Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the ...
QNRX READ THE FULL QNRX RESEARCH REPORT U.S. and International Sites participating in QRX003 NS study, Expanding to study QRX003 for additional indications and in younger patient populations Quoin ...
Today, Prof. Howard Feldman presented revised diagnostic criteria for Alzheimer's disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid on behalf of the International ...